

28 February 2017

Suite 1, 1233 High Street  
Armadale, VIC 3143

---

**Imugene announces half-year results for period ended 31 December 2016**

---

Operational and Financial highlights during the period included the appointment of:

- New strategic partnership with the Baker Institute investigating the opportunities for small molecules in immuno-oncology
- Four new mimotope patents filed to expand Imugene pipeline into B-cell vaccine compositions and franchise
- Successful \$3.2M private placement with sophisticated and institutional investors
- Cash and cash equivalents 31 December 2016: Up 41% on pcp to \$3.8m
- Phase 1b/2 trial in patients with metastatic gastric cancer to recruit in 2017.
- Loss for the 6 months to 31 December 2016: Up 45.00% on previous comparable period ('pcp') to \$1.49m;

Imugene Limited (ASX: IMU) announced a total loss of \$1.49m on its operations for the half-year period ending on 31 December 2016. During the period, the Company incurred expenditure of \$2.27m, which was offset in large part by an expected rebate of \$0.77m under the Australian Government's R&D tax incentive scheme. The majority of expenses, being \$1.65m, were incurred on research & development, with the balance being payroll and administration costs.

**About Imugene and HER-Vaxx**

Imugene (ASX: IMU) is a clinical stage immuno-oncology company headquartered in Melbourne, Australia. Its lead product is HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. The company is also developing mimotope-based immunotherapies against validated and new oncology targets. HER-Vaxx is a cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers. This unique immunotherapy, developed by leading scientists at the Medical University of Vienna in Austria, is a peptide vaccine constructed from various B cell epitopes of HER-2/neu. It has been shown in pre-clinical work and in one Phase 1 study to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target. HER-Vaxx's successful Phase 1 study was in patients with breast cancer and the next stage of development will be a Phase 1b/2 study in patients with gastric cancer initiating in 2016. In January 2016 Imugene announced a new partnership with the Medical University of Vienna to discover and develop mimotope-based immunotherapies against validated and new oncology targets. This partnership has the potential to create B Cell peptide vaccines that would replace or augment conventional monoclonal antibodies. In December 2016, Imugene announced an exclusive agreement with the internationally respected Baker IDI Heart & Diabetes Institute in Melbourne to research, develop and commercialise a portfolio of small molecule arginine modulators for oncology. For further information please contact: